# The Clinical Study of Adalimumab Combined With Other Anti-tumor Therapy as a Treatment for Resectable Non-small Cell Lung Cancer

Source: https://onco.cc/trials/nct07704645/  
OnCo record `nct07704645` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of adebrelimab in lung cancer, run by Suzhou Suncadia Biopharmaceuticals Co., Ltd., not yet recruiting.

## Summary

The Clinical Study of Adalimumab Combined With Other Anti-tumor Therapy as a Treatment for Resectable Non-small Cell Lung Cancer is a phase 2, interventional study registered as NCT07704645 by Suzhou Suncadia Biopharmaceuticals Co., Ltd., with a registry enrolment figure of 180 participants, started 2026-08 and due to reach its primary completion in 2028-06. Interventions recorded: Adebrelimab Injection combined with SHR-1826 Injection combined with SHR-8068 Injection; Adebrelimab Injection combined with HRS-7058 Capsule. Conditions listed: Resectable Non-small Cell Lung Cancer. Primary outcome: Pathological complete response (pCR) rate: pCR is defined as the absence of any residual tumor at the time of surgical resection.. Lung eligibility wording from the registry: "Patients with histopathologically or cytologically confirmed Stage II, IIIA, or select Stage IIIB (AJCC 9th edition) non-small cell lung cancer who are candidates for curative-intent R0 surgical resection". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-25
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT07704645
- Phase: 2
- Setting: A Phase II Clinical Study of Adebelizumab Combined With Other Anti-tumor Treatments as a Perioperative Treatment for Resectable Non-small Cell Lung Cancer
- Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- Enrolled: 180

## Sources

- ClinicalTrials.gov NCT07704645: https://clinicaltrials.gov/study/NCT07704645

## Connected records

- cancers: [Resectable stage I to III non-small-cell lung cancer](https://onco.cc/cancers/resectable-nsclc/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Adebrelimab](https://onco.cc/drugs/adebrelimab/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07704645.json